Russian drugmaker R-Pharm eyes buying Takeda plant in Yaroslavl
Russian drugmaker R-Pharm is considering acquiring the manufacturing facility of Japanese pharma giant Takeda (TYO: 4502) located in Yaroslavl, Russia, The Pharma Letters local correspondent reports.
According to the Russian Vedomosti business paper, citing on its sources close to the companies, negotiations are currently underway. Takeda wants to sell the plant due to sanction restrictions due to Russia’s military action in Ukraine, but it does not plan to completely leave Russia.
The plant itself was launched back in 2013, with its capacity at 90 million ampoules and more than 3 billion tablets per year. It produces drugs for the treatment of oncological, gastroenterological, neurological and rare diseases.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze